摘要
目的：对比观察艾迪注射液联合PP方案化疗与单用PP方案化疗治疗晚期非小细胞肺癌（non－smal cel lung cancer，NSCLC）的临床疗效、生活质量及毒副反应。方法56例晚期非小细胞肺癌患者随机分为试验组及对照组，每组28例。试验组：紫杉醇175mg／㎡ d1＋顺铂25mg／㎡ d1－3联用艾迪注射液100ml ＋5％GS 250ml静滴 d1－14， Q3w。对照组：紫杉醇175mg／㎡ d1＋顺铂25mg／㎡ d1－3，Q3w。化疗2周期后评价疗效，化疗前及化疗2周期后评价生活质量，每周期评价不良反应。结果试验组和对照组有效率分别为35．71％和28．57％，差异无统计学意义（P＞0．05），疾病控制率分别78．57％和53．57％，差异具有统计学意义（P＜0．05）。治疗后试验组生活质量改善效果明显优于对照组（P＜0．05）。试验组的白细胞减少、恶心呕吐及肝功能损害三方面不良反应较对照组明显减轻（P＜0．05）。结论艾迪注射液联合PP方案化疗可以提高患者的疾病控制率，改善生活质量，减轻化疗相关毒副反应。
Abstract
Objective To compare the clinical ef ect,quality of life and toxicity between Aidi injection combined with PP regimen and PP regimen alone in treating advanced non-smal cel lung cancer (NSCLC)patients.Methods 56 advanced NSCLC patients were randomly divided into 2 groups with 28 cases in each group.Test group:paclitaxel 175mg/m2 ivgt d1 +cispla-tin 25mg/m2 ivgt d1 -3 combined with Aidi injection 100ml+5%GS 250ml ivgt d1 -14,Q3w.Control group:paclitaxel 175mg/m2 ivgt d1 +cisplatin 25mg/m2 ivgt d1 -3,Q3w.The clinical response was assessed after two cycles.The quality of life was assessed at baseline and after two cycles.Toxicity was assessed every cycle.Results The overal response(RR)rates were 35.71% and 28.57% in test group and control group (P>0.05)respectively.The disease control rates(DCR)were 78.57%and 53.57%in test group and control group (P<0.05)respec-tively.The quality of life of the test group was improved more significantly than that of the control group (P<0.05).The adverse reactions of test group,such as leukopenia,gastrointestinal adverse reactions and liver damage,were significantly reduced compared with control group (P<0.05).Conclusion Aidi injection which combined with PP regimen in treating advanced NSCLC could increase the disease control rate,improve the quality of life,and reduce the incidence of adverse reactions.
NETL
NSTL
维普
万方数据